Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Monday lulv 8

MoPeB3246 Maximizing adherence and prevention of
resistance through directly observed therapy:
DOT-HAART
F Leandre1, P Farmer2, I S Mukherjee2,
M S Claude1, P Nevill, M C Smith Fawzi2,
S P Koenig2, A Castro2, M C Becerra2, M Addo2,
B Walker2, I Y Kim2 (Haiti; 2United States)
MoPeB3247 Estimating Quality of Life and Health Utility Using
Visual Analog Scale (VAS) Scores in the Adult
AIDS Clinical Trials Group Longitudinal Linked
Randomized Trials (ALLRT) Cohort (A500ol)
j M Mrus, M S Yi, J Tsevat, A W Wu, H Gorski,
R Zackin, KA Freedberg (United States)
MoPeB3248 The perception of loss of functional ability for
people living with AIDS Dementia Complex in
supported accomodation
Monday K L Greqory, D P Gibbs (Australia)
MoPeB3249 HAART from the patient's perspective: their
impact on every day life
G Meystre-Agustoni, F Dubois-Arber, P Cochand,
A Telenti, P Morency, A Jeannin, B Spencer, Swiss
HIV Cohort Study (Switzerland)
MoPeB325o Sensio study: assessment of late
neuropsychiatric adverse reactions (NPAR) to
efavirenz
P Lochet, H Peyriere, J M Mauboussin, B Delmas,
A Lotthe, J Reynes (France)
MoPeB3251 Self-perception of body's alterations in HIVinfected patients
C P Santos ET Eid, YX Felipe, L Maester,
M S Oliveira, M I B Lopes, A A C Segurado,
0 H M Leite (Brazil)
MoPeB3252 From here to uncertainty: national shifts in ARV
uptake, interruptions, experience and attitudes
J W Grierson S Misson, K Mc Donald, M Hurley,
J Willis, M L O'Brien (Australia)
MoPeB3253 Perceptions of highly active antiretroviral therapy
(HAART) among HIV positive men who have been
recommended treatment
V Cooper R Home, G Gellaitry, N Lambert,
M Fisher (United Kingdom)
MoPeB3254 Sexual dysfunction in people treated with
antiretroviral treatment
W Schrooten, C Dreezen, D Asboe, M V Gordillo,
L Schdinnesson, R Colebunders (Belgium)
MoPeB3255 HIV-school: education of HIV-infected children
and teenagers in a country-side camp
C Rals6rd A Hjdlmdahl-Trygg, L Naver,
A B Bohlin (Sweden)
MoPeB3256 Care and treatment of HIV/AIDS in nondocumented African migrants in Berlin Germany:
a dilemma between public health and legal
priorities
A Edubio, P Narimani, CA Ihekweazu', G
Broring2 (Germany; 2Netherlands Antilles)
MoPeB3257 Incidence rates of active tuberculosis among
opiate users in northern Thailand
P Sawanpanvalert, H Yanai, S Moolphate,
S Nedsuwan, 0 Nampaisan, S Supawitkul,
S Piyaworawong (Thailand)
MoPeB3258 Efficacy and tolerance of therapy with IFNalpha/RBV and peglFN-alpha/RBV in HIV-/HCVcoinfected IVDUs
JGaelz, G Klausen, A Mall, D Schleehauf, D
Prziwara, C Cordes, S Nzimegne-Goelz (Germany)
MoPeB3259 Antiretroviral adherence barriers in a correctional
setting

S L Catz, J M Sosman, KA Scheuerell, D Crumble
(United States)

MoPeB326o Socio-demographic characteristics and response
to antiretroviral therapy among indigenous
participants in a population-based program
CL Miller K V Heath, K Chan, PM Spittal,
M V O'Shaughnessy, JS G Montaner,
M T Schechter, R S Hogg (Canada)
MoPeB3261 Overcoming social and cultural barriers to
successful HIV therapy by individually - directed
psychosocial approach that involves community
work
L Rowe C Maor, M Gilad, S Arad (Israel)
MoPeB3262 Filling the gap between homeless life and the
conventional health system
M Bary, K Asselah, S Catrix, M Djuric,
A Boukhemair, M Gentilini (France)
MoPeB3263 Clinical and immune recovery during
antiretroviral therapy among HIV-infected
prisoners
J M Sosman I Baker, S L Catz, M JBrondino
(United States)
MoPeB3264 Face-to-face negotiations for patients' interests
P Marques', E Trenado2, S Collins3, F Houyez2
(Portugal; 2France; 3United Kingdom)
MoPeB3265 Predictors of cumulative time on HAART among
the homeless and marginally housed
ED Riley, S Perry, A R Moss, D Guzman, R A Clark,
E Charlebois, D R Bangsberg (United States)
MoPeB3266 Group support for doctors with HIV infection: 12
year evaluation
B Hedge (New Zealand)
MoPeB3267 HIV-treatment for injecting drug users: applying
the WHO interim ARV treatment guidelines
GA Weiler, B Vareldzis', J Perriens', M Vitoria2,
B G Gazzard3, V Poznyak (Switzerland; 2Brazil;
3United Kingdom)
MoPeB3268 The limitations of the legal framework governing
prescription of opioid substitution treatment in
France
O Maguet A Guichard, C Calderon, H Gaigi,
J Soletti (France)
MoPeB3269 Delay in medical care after HIV diagnosis in men
of color who have sex with men
JC Hodges K Khoshnood, D Stevens
(United States)
MoPeB327o Psychiatric profile of 349 HIV/AIDS patients in
the HAART era
J L Zirulnik, P Patterson, P Cahn (Argentina)
MoPeB3271 Treated versus untreated HIV positive patients in
an urban emergency department
G H Kimel E Grafstein, J S Montaner, K]J P Craib,
T Regev, A Palepu, R Hogg, C H Sherlock,
J Christenson, G Innes, M O'Shaughnessy
(Canada)
MoPeB3272 Physician specialization and antiretroviral therapy
for HIV: adoption, use, and adherence in a national
probability sample of persons infected with HIV
BE Landon, IB Wilson, MD Wong, SE Cohn,
C I Fichtenbaum, N S Wenger, SA Bozzette,
M F Shapiro, PD Cleary (United States)
MoPeB3273 From constructive dialogue to implementation of
HIV care programs in developing countries
S Muyingo1, H Coovadia2, D Ochola, I Ladner3,
I Saba4 (1Uganda; 2South Africa; 3France; 4lreland)
MoPeB3274 Assessing the access to antiretroviral drugs in
Chile through the national viral load database
C Sepdlveda, X Anglaret2, 6 Berrios1, M Rios,
E Navarrete1, D Graells', A Henrfquez, and the

Chilean Drug Access Initiative ANRS Study Group'
(Chile; 2France)

Final Program